Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol
European Journal of Neurology · 2025
DOI: 10.1111/ene.70097 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von John P Bourke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Freeman Hospital, Newcastle Hospitals Foundation Trust & John Walton Muscular Dystrophy Research Centre, Newcastle Universi…. Hauptthemen laut MEDLINE: Bisoprolol, Perindopril, Muscular Dystrophy, Duchenne, Cardiomyopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Duchenne UK, Duchenne Research Fund.
Abstract (Originalsprache)
Introduction
It is uncertain whether using cardiac drugs prophylactically in combinations for DMD is better than ACE‐inhibitor alone. Our previous study showed no differences in left ventricular function between perindopril‐bisoprolol and matched placebo after 36 months.
Methods
This study aimed to determine whether heart measures diverged after 60‐month total follow‐up. All participants had commenced open‐label perindopril and bisoprolol when the original study ended. All were reconsented for access to heart measures, undertaken as part of their clinical care. The primary outcome was the change in echo‐measured ventricular ejection fraction from baseline according to original randomization.
Results
Of 75 participants reported originally, 65 (aged 16 ± 2.5 years) were re‐recruited and had data for analysis. Adjusted primary outcomes included 44 participants (original arms: ‘active’ 21; ‘placebo’ 23), 48 for secondary outcomes, and 65 for ‘headcount’ analysis of those with ventricular dysfunction. Absolute LVEF% values reduced in both groups (‘active’: 62.5% ± 5.6% to 53.8% ± 4.0%; ‘placebo’: 60.6% ± 4.9% to 50.4% ± 8.5%). Despite trends favoring earlier introduction of therapy, change from baseline was similar between groups (adjusted mean difference: ‐7.7 (95% CI ‐16.4 to1.0%)). However, more in the ‘placebo’ arm had died, had reduced LVEF%, and were taking additional heart medications.
Conclusion
While some patients may have benefited from ‘early’ (active) as opposed to ‘delayed’ (placebo) initiation of perindopril and bisoprolol, group‐mean ventricular function did not differ between study arms after 60 months. Small numbers, absence of a control group, insensitivity of echo‐ejection fraction, and additional drug use probably prevented divergence between groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Freeman Hospital, Newcastle Hospitals Foundation Trust & John Walton Muscular Dystrophy Research Centre, Newcastle University, and Newcastle Hospitals Foundation Trust, Newcastle upon Tyne, UK.
- John Walton Muscular Dystrophy Research Centre, Newcastle University, and Newcastle Hospitals Foundation Trust, Newcastle upon Tyne, UK.
- Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
- NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, & Great Ormond Street Hospital Trust, London, UK.
- Newcastle Joint Research Office, Newcastle University/The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- Department of Paediatric Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
ORCID-Profile: John P Bourke
Förderung
- Duchenne UK
- Duchenne Research Fund
Zitieren
APA
Bourke, J. P., Bryant, A., Landon, G., Burn, A., Spinty, S., Quinlivan, R., Alhaswani, Z., Chadwick, T., Muntoni, F., Guglieri, M., & DMD Heart Study Group (2025). Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol. European Journal of Neurology. https://doi.org/10.1111/ene.70097
Vancouver
Bourke JP, Bryant A, Landon G, Burn A, Spinty S, Quinlivan R, et al. Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol. European Journal of Neurology. 2025. doi:10.1111/ene.70097
BibTeX
@article{Bourke2025,
author = {Bourke, John P and Bryant, Andrew and Landon, Gregory and Burn, Alexis and Spinty, Stefan and Quinlivan, Ros and Alhaswani, Zoya and Chadwick, Thomas and Muntoni, Francesco and Guglieri, Michela and DMD Heart Study Group, DMD Heart Study Group},
title = {Preventing Cardiomyopathy in Duchenne Muscular Dystrophy: Long‐Term Follow‐Up of Patients in the Randomised, Placebo‐Controlled Drug‐Trial of Perindopril and Bisoprolol},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70097}
}
EUVIMED